{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-039285","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.539032+00:00","generated_at":"2026-06-30T01:07:53.657665+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data","bullets":["Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.","Cash, equivalents, and marketable securities $79.6M at June 30, up from $19.2M Dec 31, 2020.","Preclinical data for LP-184 showed 93% avg tumor volume reduction in pancreatic cancer models.","Preparing LP-300 Phase 2 trial site selection and GMP batch for NSCLC in Q3 2021.","Reacquired LP-100 (Irofulven) rights from Allarity; $1M upfront plus up to $16M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-039285","json":"https://secwatch.observer/filing/0001213900-21-039285.json","markdown":"https://secwatch.observer/filing/0001213900-21-039285.md","text":"https://secwatch.observer/filing/0001213900-21-039285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000121390021039285/0001213900-21-039285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000121390021039285/ea144935-8k_lanternpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:07:53.657665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}